GlassScriptPhysician profile
Zev R Maycon
NPI 1275687881
$11,210.48
in general payments reported to CMS, 2019-2025
44 companies · $1,424 in 2025
The $1,424 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,476 · 2020: $1,375 · 2021: $2,099 · 2022: $1,721 · 2023: $1,421 · 2024: $1,695 · 2025: $1,424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,524 · Education: $15.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,523.78 |
| Education | $15.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,965.69 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,757.54 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,619.12 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $683.23 | 2019-2024 | Stelara, Remicade, Simponi Aria |
| Daiichi Sankyo INC. | $593.03 | 2019-2025 | Injectafer |
| Genzyme Corporation | $386.64 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $337.04 | 2019-2024 | Linzess |
| Qol Medical, LLC | $280.98 | 2019-2024 | Sucraid |
| Ardelyx, INC. | $215.84 | 2022-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $206.27 | 2019-2024 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $165.97 | 2022-2023 | |
| Redhill Biopharma INC. | $150.94 | 2020-2022 | |
| Pfizer INC. | $146.45 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $136.34 | 2020-2024 | Dificid |
| Medtronic, INC. | $110.12 | 2023-2025 | Interstim, Gi Genius |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $109.37 | 2019-2020 | |
| Ucb, INC. | $105.73 | 2019-2020 | |
| Vivus LLC | $104.33 | 2021-2025 | Qsymia |
| Alfasigma USA, INC. | $98.33 | 2020-2021 | |
| Madrigal Pharmaceuticals | $96.77 | 2025 | Rezdiffra |
| Celgene Corporation | $85.39 | 2021-2024 | Zeposia |
| Romark Laboratories, Lc | $74.15 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.02 | 2023-2024 | Cyltezo |
| Phathom Pharmaceuticals, INC. | $67.48 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $64.97 | 2024-2025 | Vowst, Zenpep |
| Concordia Pharmaceuticals INC. | $60.94 | 2019 | |
| Lilly USA, LLC | $52.25 | 2024-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $51.10 | 2024-2025 | Iqirvo, Bylvay |
| Celltrion USA INC. | $48.86 | 2024-2025 | Vegzelma, Zymfentra |
| Evoke Pharma, INC. | $47.83 | 2020-2025 | |
| Ferring Pharmaceuticals INC. | $42.47 | 2020-2023 | Rebyota |
| Shire North American Group INC | $41.00 | 2019 | |
| Braintree Laboratories, INC. | $29.16 | 2021-2025 | Suflave, Sutab |
| Echosens North America, INC. | $25.00 | 2021 | |
| Amgen INC. | $24.14 | 2021 | |
| Sandoz INC. | $22.98 | 2024 | Hyrimoz |
| Axonics, INC. | $20.01 | 2021 | |
| Eisai INC. | $18.75 | 2019 | |
| Horizon Therapeutics Plc | $16.60 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $16.53 | 2025 | Dupixent |
| Dova Pharmaceuticals | $16.44 | 2019 | |
| Csl Behring | $16.07 | 2021 | |
| Fresenius Kabi USA, LLC | $14.98 | 2024 | Idacio |
| Gilead Sciences, INC. | $14.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zev Maycon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.